Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMMC - Industry leading Diabetes Drug -- Ignore unavailable to you. Want to Upgrade?

To: Richard Strutz who wrote (34)	4/28/1999 10:37:00 AM
From: Rich Kaiser	Respond to of 55

Hey Rich, I know that you sold AIRP to buy Biotech... and You know how I felt about that decision! I won't let you down in terms of IMMC but you also know how I feel about the PR-firm handling the Biotech gig. IMMC will more forward... I continue to get a lot of interest in IMMC because of good fundamentals. I can understand your frustration level but I'm with you in generate price appreciation in IMMC. Rich

To: Richard Strutz who wrote (34)	5/27/1999 3:02:00 PM
From: Grant Cash	Read Replies (1) \| Respond to of 55

HOT DOPE UPDATE: IMMC- Immunis Corp.- Last night CNN Money Line reported the problems associated with Type-II diabetes patients who take the Warner-Lambert Drug, Rezulin. The report revealed the numerous ill effects and deaths associated with the use of the drug. Additionally, CNN mentioned another REVOLUTIONARY drug that actually had little to no side effects for Type-II patients. Unfortunately, CNN did not mention the name of the drug and/or the manufacturer. DIAB-II, produced by Biotech, maintains stable interaction within the body's many biochemical reactions. Chosen DRUG of THE YEAR in China, the DIAB-II drug proves itself to be a WINNING treatment for Type-II diabetes. DIAB-II works with muscle cells, has non-hazardous side effects, and will not cause obesity problems which are often associated with the majority of other Type-II oral treatments. Currently, the Brazilian FDA reviews the trial-testing documents conducted with DIAB-II on Brazilians infected with Type-II. Unconfirmed reports revealed that these Brazilian tests went extraordinary well and that Biotech, in the ensuing weeks ahead, should recieve the approvals to sell the DIAB-II drug. Remembering the fact, that Rezulin (Warner-Lambert) and Avandia (Smith-Kline), the two most common oral treatments for Type-II, CANNOT be sold in Brazil. Injection of low dosages of insulin remains the current treatment for Type-II patients in Brazil. Noteworthy, IMMC receives a 25% payment from Biotech on all sales and distribution (outside of China) of the DIAB-II drug. IMMC expects to make an extraordinary amount of revenue from this 25% royalty agreement with Biotech. IMMC has NO debt, very small overhead, a small float around 700,000 shares (6.5 million fully diluted restricted stock until December 2000), and great exposure with both the medical and investment communities. IMMC stock continues to move forward from the VALUE seeking investors who understand the fundamentals involved with this Pharmaceutical action! From an analytical approach, IMMC presents itself to be a RIPE take over candidate! IMMC trade on the OTCBB.